Preconditioning of calves

A high frequency of diseases in the veal industry is caused by diseases which are induced by several factors which are caused or at least influenced by errors of management. In order to comply with the political goal of a diminution of the use of antimicrobials in the veal industry (ban of growth promoters), errors of housing and of nutrition, damaging influences of the microclimate and hazardous commercial substances should be eliminated. Further measures of prophylaxis are discussed.     

Preparing Holstein steer calves for the feedlot.

It is increasingly common to raise Holstein steer calves for entry to feedlot production systems rather than more traditional milk-fed veal production systems. Providing adequate nutritional support for the maintenance and growth of Holstein calves is essential in preparing them for a commercial feedlot environment. In this article, the dietary requirements of preruminant calves are reviewed and examples of evaluating milk diets for Holstein calves are detailed. The importance of the transition between milk feeding and grain-forage diets is discussed. Aspects of disease prevention, such as coccidiosis control and colostrum feeding, are also discussed. The reader will gain practical tools to use in preventive medicine programs involving Holstein steers being prepared for commercial feedlots.     

B-vitamin supplementation of diets for feedlot calves

B-vitamin supplementation of diets for 144 shipping-stressed crossbred calves (116 kg) at levels up to 10 times that recommended for growing pigs did not influence (P greater than .20) weight gain or feed conversion during a 56-d receiving trial. However, vitamin supplementation tended (P less than .10) to reduce morbidity. In a second trial, supplemental B-vitamins had no effect (P greater than .20) on efficiency of microbial growth or site and extent of digestion of organic matter, acid detergent fiber and N. Supplemental dietary riboflavin, niacin, folic acid, B12 and ascorbic acid were largely metabolized [degraded and (or) absorbed] anterior to the small intestine, with escape values of 1, 3, 10 and 0% of added vitamins, respectively, while dietary B6 and biotin largely escaped the rumen. Thiamine and pantothenic acid were intermediate in ruminal escape (52 and 22%, respectively). Small intestinal absorption of thiamine, niacin, riboflavin, B6 and B12 averaged 75, 79, 25, 79 and 48%, respectively. Coefficients for ruminal escape and microbial synthesis for each B-vitamin were calculated using the slope-ratio technique. Measured flows for thiamine, riboflavin and B12 in a third experiment were similar to flows predicted from escape and synthesis equations, though flow of niacin and B6 were under-predicted by 37 and 44%, respectively. Results are interpreted to indicate that intestinal B-vitamin supply can be predicted based on dietary composition and intake.     

Phosphorus requirement of finishing feedlot calves

Dietary P supplied to feedlot cattle is important because an inadequate supply will compromise performance, whereas excess P may harm the environment. However, P requirements of feedlot cattle are not well documented. Therefore, 45 steer calves (265.2+/-16.6 kg) were individually fed to determine the P required for gain and bone integrity over a 204-d finishing period. The basal diet consisted of 33.5% high-moisture corn, 30% brewers grits, 20% corn bran, 7.5% cottonseed hulls, 3% tallow, and 6% supplement. Treatments consisted of 0.16 (no supplemental inorganic P), 0.22, 0.28, 0.34, and 0.40% P (DM basis). Supplemental P was provided by monosodium phosphate top-dressed to the daily feed allotment. Blood was sampled every 56 d to assess P status. At slaughter, phalanx and metacarpal bones were collected from the front leg to determine bone ash and assess P resorption from bone. Dry matter intake and ADG did not change linearly (P > 0.86) or quadratically (P > 0.28) due to P treatment. Feed efficiency was not influenced (P > 0.30) by P treatment and averaged 0.169. Plasma inorganic P averaged across d 56 to 204 responded quadratically, with calves fed 0.16% P having the lowest concentration of plasma inorganic P. However, plasma inorganic P concentration (5.7 mg/dL) for steers fed 0.16% P is generally considered adequate. Total bone ash weight was not influenced by dietary P for phalanx (P = 0.19) or metacarpal bones (P = 0.37). Total P intake ranged from 14.2 to 35.5 g/d. The NRC (1996) recommendation for these calves was 18.7 g/d, assuming 68% absorption. Based on performance results, P requirements for finishing calves is < 0.16% of diet DM or 14.2 g/d. Based on these observations, we suggest that typical grain-based feedlot cattle diets do not require supplementation of inorganic mineral P to meet P requirements.     

Growth-promoting systems for heifer calves and yearlings finished in the feedlot

In a 172-d finishing trial (Exp. 1), 210 recently weaned crossbred heifers were allotted to six growth promotant treatment groups, involving implanting initially with Synovex-C (C) or H (H) followed by reimplanting with Finaplix-H (F) or H and F. Melengestrol acetate (MGA) was provided in the diet to four of the treatment groups. Heifers fed MGA and administered only F as the terminal implant had the greatest (P = .01) number of mature ovaries with follicles but also had lower (P = .01) gain/DMI. In a 182-d finishing study (Exp. 2), 270 recently weaned crossbred heifers were allotted to the following six implant (d 0)/ reimplant (d 70) groups using no implant (N), Ralgro (R) or H: N/R, R/H, R/R, N/R, H/H and R/R for Treatments 1 through 6, respectively. On d 70, all heifers were implanted with F. Heifers were fed MGA from d 70 to 182 (Treatments 1, 2, and 3) or for the entire trial (Treatments 4, 5, and 6). Implanting on d 0 increased (P < .05) overall ADG. Differences (P > .05) in performance were not found between MGA treatment groups. Using an H implant/reimplant regimen decreased (P = .01) ovarian and(or) follicular development when compared with an R implant/reimplant regimen. In a 126-d finishing trial (Exp. 3), 360 crossbred yearling heifers were used to evaluate F and estrogen (Implus-H) implants when used in combination with an MGA feeding program. Heifers receiving only F in combination with MGA had greater (P < .05) ADG, whereas all heifers fed MGA had greater (P < .05) gain/DMI than heifers not fed MGA. These data suggest that feeding MGA was not beneficial for young heifers, particularly if they are provided an initial estrogenic implant followed by a second implant. In older (yearling) heifers, increased gains and gain/DMI were obtained by feeding MGA and implanting initially or 56 d later with F.     

Prophylactic medication of feedlot calves with tilmicosin

The parenteral administration to calves of the antibiotic tilmicosin either on arrival at a feedlot or 72 hours later was evaluated in a group of 308 steer calves. The calves were allotted to 24 pens so that there were eight replicates of the two medicated groups and eight replicates of the control group. The need for veterinary treatment was reduced significantly (P less than 0.05) during the first month of the feeding period in the two medicated groups. The medicated groups had an improved average daily weight gain (P less than 0.01) over the trial period compared with the non-medicated animals. This improved average daily gain by the medicated groups was not reduced when animals with respiratory disease were excluded from the calculations. The medicated groups also had an improved feed conversion efficiency (P less than 0.01) over the first 60 days of the feeding period compared with the non-medicated animals.     

Efficacy of parenteral antibiotics for disease prophylaxis in feedlot calves

Trimethoprim-sulfadoxine (TMPSDX) and two formulations of oxytetracycline (OTC) were examined for their prophylactic efficacy in feedlot calves when given by intramuscular injection on arrival at a large commercial feedlot. The study included 2,112 high-risk feeder calves that developed disease early in the feeding period. Both formulations of OTC reduced bovine respiratory disease morbidity during the first two weeks on feed and for the entire feeding period by 15-19% (p<0.05), and they also reduced all fatal fibrinous pneumonia by 67% and 84% (p<0.05). All three drugs significantly reduced all fatal disease in animals first treated during the second week on feed, but not for the overall feeding period. Oxytetracycline with 2-pyrrolidone reduced the incidence of all fatal disease by 44% (p<0.05) during the entire feeding period. The case fatality risk for calves first treated during the second week on feed was lower (p<0.05) in the TMPSDX group and in the OTC with polyvinyl-pyrrolidone group.     

Prophylactic tilmicosin medication of feedlot calves at arrival

The parenteral administration of the antibiotic tilmicosin given on arrival at a feedlot was evaluated in a group of 304 steer calves. These calves were allotted to 24 pens so that there were 12 replicates of both the control and medicated groups. The treatment rate was reduced significantly during the first five days (p < 0.05) and during the first month (p < 0.01) of the feeding period in the medicated group. The average days from arrival until first treatment for respiratory disease was increased to 21 days in the medicated group compared to 9 days (p < 0.01) for the controls. The medicated group had improved average daily gain (p < 0.01) and feed efficiency (p < 0.01) over the trial period when compared to the nonmedicated animals.     

Bovine adenovirus type-3 infection in feedlot calves

The frequency of bovine adenovirus type-3 (BA3) infection in 84 of 165 light feeder calves and the possible role of BA3 in inducing febrile disease and affecting weight gain performance were studied for 56 days after the calves entered a feedlot. Samples of blood for serotesting were obtained periodically, and samples for virus isolation were collected on days 28 and 56. At the time the calves entered the feedlot, 17.8% (15 of 84) had serum virus-neutralizing antibodies to BA3. During 56 days, 54.8% (46 of 84) seroconverted to BA3. Of these seroconversions, 87% took place during the first 28 days. Bovine adenovirus type-3 was isolated from 2 calves (1 isolate each on days 28 and 56). Pyrexia (greater than or equal to 39.2 C) was observed more often in BA3-infected calves than in noninfected calves. However, there was no significant (P less than 0.05) difference in weight gain between the BA3-infected and noninfected calves.     

Vitamin E supplementation of newly arrived feedlot calves

Seven hundred fifteen crossbred (primarily British) calves purchased in southern Oklahoma and northern Texas auction barns were received at the Willard Sparks Beef Research Center, Stillwater, OK, and used to study effects of duration (days) of vitamin E feeding during a 42-d receiving period on animal performance, health, and serum cholesterol and vitamin E concentrations. Upon arrival, calves were blocked by load (seven loads), sorted by BW (light, n = 4 pens per load; and heavy, n = 4 pens per load), and assigned randomly to one of four dietary treatments (n = 2 pens per load; 14 pens per treatment). Experimental diets were formulated to provide 2,000 IU.calf(-1).d(-1) of supplemental vitamin E (dl-alpha-tocopherol acetate) for 0 (CON), 7 (E7), 14 (E14), or 28 (E28) d. Vitamin E was delivered in a pelleted supplement that was added to the basal diet in decreasing concentrations as DMI increased (2.0 kg of DMI = 6%; 4.0 kg of DMI = 4%; and 6.0 kg of DMI = 2%). Serum samples were collected on d 0, 14, 28, and 42 for determination of cholesterol, alpha-tocopherol (d 0, 28, and 42), and antibody (IgG) concentrations. Duration of vitamin E supplementation did not affect ADG (0.98 kg/d; P = 0.56) or G:F (0.189; P = 0.87). Serum cholesterol concentrations decreased (day effect; P < 0.001) for all treatments from d 0 (average = 127 mg/100 mL) to 14 (average = 62 mg/100 mL). Serum alpha-tocopherol decreased (day effect; P < 0.001) from d 0 (5.2 microg/mL) to 28 (1.8 microg/mL); however, on d 28, a greater (P < 0.001) serum alpha-tocopherol concentration was observed for E28 (3.4 microg/mL) calves than for CON (1.1 microg/mL), E7 (1.2 microg/mL), or E14 (1.5 microg/mL) calves. Respiratory disease was diagnosed in 64.6% of calves in this study. Medical costs were less (P = 0.08) for calves fed vitamin E for 28 d (4.88 dollars/calf) than for calves fed the control diet (6.29 dollars/calf). Carcass characteristics were not affected (P = 0.19 to 0.88) by dietary treatments. Supplemental vitamin E formulated for 2,000 IU.calf(-1).d(-1) had little influence on performance and overall health status of calves under our experimental conditions; however, the increased serum concentrations of alpha-tocopherol when vitamin E was fed for 28 d suggests that any potential effects of vitamin E on health status might be time-dependent.     

A comparison of florfenicol and tulathromycine for the treatment of undifferentiated fever in feedlot calves

The purpose of this study was to compare the relative cost-effectiveness of florfenicol with that of tulathromycin for treatment of undifferentiated fever (UF) in feedlot calves at ultra-high risk of developing UF that receive metaphylactic tulathromycin on arrival at the feedlot. Calves that received therapeutic florfenicol had lower overall mortality (P=.045) and bovine respiratory disease mortality (P=.050) compared with calves that received therapeutic tulathromycin, but no significant differences were detected in feedlot performance, carcass characteristics, or other animal health variables. There was a net advantage of Can$41.19/treated animal in the florfenicol group versus the tulathromycin group. This study demonstrates that it is more cost-effective to use florfenicol than tulathromycin for the initial treatment of UF in feedlot calves at ultra-high risk of developing UF that receive on-arrival metaphylactic tulathromycin.     

Conglutinin and immunoconglutinin titers in stressed calves in a feedlot

OBJECTIVE: To determine whether increased conglutinin titers are evident in stressed calves that do not develop respiratory tract disease in feedlots, compared with respiratory tract disease, and to determine the increase in immunoconglutinin titers. ANIMALS: 101 mixed-breed beef calves. PROCEDURE: Calves were processed at 4 farms of origin and allowed to remain with their dams for another 100 days. Calves from each farm were brought to a centrally located order-buyer barn. In a feedlot, 101 calves were assigned to pens and observed daily for clinical signs of acute respiratory tract disease. When sick calves were detected, they were treated with antibiotics and isolated in a pen for 4 days. Conglutinin and immunoconglutinin titers were determined for all calves. RESULTS: During the 28-day study, 73 calves developed respiratory tract disease, whereas 28 calves remained healthy. Mean conglutinin titers differed significantly among calves from the 4 farms. Significant differences were not detected in conglutinin titers among calves on the basis of sex, morbidity, or vaccination status against Mannheimia haemolytica at each farm, the order-buyer barn, or the feedlot on days 8, 15, and 28 after arrival. Immunoconglutinin titers in calves differed significantly among farms and morbidity status. CONCLUSIONS AND CLINICAL RELEVANCE: Mean conglutinin titers in calves do not appear to be associated with the incidence of acute respiratory tract disease; however, increased immunoconglutinin titers appear to be associated with recovery of stressed calves from respiratory tract disease during the first 15 days after arrival in a feedlot.     

Comparative cost-effectiveness of ivermectin versus topical organophosphate in feedlot calves

A study was conducted in a commercial feedlot in western Canada to evaluate the impact of treatment with ivermectin versus a topical organophosphate on growth rate and feed efficiency in calves entering a feedlot at an average 275 kg liveweight.

A total of 9527 head of cattle was used. Variables measured included average daily gain, average days occupation, and feed conversion.

Ivermectin treated animals gained an average 0.08 kg per day more than those treated with topical organophosphate. In addition, they required an average 0.23 kg less feed/kg gain. Based on an average 227 kg of gain, this would result in 11 fewer days occupation and 52.3 kg less feed for ivermectin treated animals. This equaled a net benefit of $7.04 per head over treatment costs for ivermectin treatment versus topical organophosphate.

     

Evaluation of health status of calves and the impact on feedlot performance: assessment of a retained ownership program for postweaning calves

The objective of this study was to evaluate animal health status at entry to a feedlot against feedlot performance and carcass value. There were 24 herds represented by 417 calves in a retained ownership program. The health status at entry was represented by the levels of serum antibody to infectious bovine rhinotracheitis virus (IBRV), bovine viral diarrhea viruses 1 and 2 (BVDV1a, BVDV2), parainfluenza 3 virus (PI3V), bovine respiratory syncytial virus (BRSV), Mannheimia haemolytica, and Pasteurella multocida, as well as by the presence of virus in nasal swabs and blood leukocytes and the presence of bacteria in nasal swabs. The presence or absence of viruses or bacteria at entry did not predict subsequent illness. However, there were predictors of illness severity (number of treatments) and performance parameters of feedlot performance. Herds with a low morbidity rate had higher levels of BVDV1a antibodies than herds with a high morbidity rate. On both an individual-animal and a herd-average basis, calves with low levels of antibody to BVDV1a and BVDV2 had increased total treatment costs. Also, for individual animals and the herd as a whole, low levels of antibody to P. multocida, BVDV1a, and BVDV2 were related to decreased net value to owner (carcass value minus total feedlot cost). Calves treated twice or more had lower levels of antibody to BVDV1a than those treated once or not at all. Differences in herd morbidity rate and treatment costs were more related to appropriate timing of vaccine (last dose at or near delivery of calf) or lack of a 2nd dose of killed vaccine. This was best illustrated by the levels of antibody to BVDV1a. The results of this study were used to formulate recommendations for the subsequent year.     

Evaluation of the efficacy of tulathromycin as a metaphylactic antimicrobial in feedlot calves

The purpose of this study was to determine the efficacy and cost-effectiveness of tulathromycin (DRAX) versus tilmicosin (MIC) or oxytetracycline (TET) as a metaphylactic antimicrobial in feedlot calves. Calves that received DRAX had significantly (P<.05) lower initial undifferentiated fever (UF) treatment and relapse rates; lower overall chronicity, overall mortality, and cause-specific mortality rates; higher average daily gains; and improved quality grades. However, calves that received DRAX also had poorer (P<.05) yield grades compared with calves that received MIC or TET and worse feed conversion compared with calves that received MIC. Net advantages in the DRAX group were 3.79CanDollars/animal and 16.96CanDollars/animal compared with the MIC and TET groups, respectively. Based on these results, DRAX is a more efficacious and cost-effective metaphylactic antimicrobial than MIC or TET in feedlot calves at ultra-high risk of developing UF. In addition, this study presents a comparison between two methods ("deads out" and "deads in") of calculating feedlot performance variables.     

A comparison of trimethoprim-sulfadoxine and ceftiofur sodium for the treatment of respiratory disease in feedlot calves

A field trial was performed to compare trimethoprim-sulfadoxine to ceftiofur sodium in the treatment of bovine respiratory disease (BRD) in feedlot calves. Five-hundred-and-fifty-five recently weaned, crossbred beef calves, with naturally occurring cases of BRD, were randomly assigned to either trimethoprim-sulfadoxine or ceftiofur sodium treatment groups. The effectiveness of the antibiotics was assessed by comparing relapse rates, three day treatment response rates, mortality rates, chronicity rates, and wastage rates. There was no statistical difference in the first or second relapse rates between the two groups. For the initial therapy, first relapses, and overall treatment episodes, a significantly greater proportion of the calves treated with ceftiofur sodium responded to three days of therapy than those treated with trimethoprim-sulfadoxine (p < 0.05). This resulted in a 10% reduction in treatment costs for calves in the ceftiofur group. There were significantly lower mortality and wastage rates attributable to BRD in the ceftiofur sodium group than in the trimethoprim-sulfadoxine group (p < 0.05). However, there were no significant differences in overall mortality, overall chronicity, or overall wastage rates between the treatment groups.     

Evaluation of florfenicol for the treatment of undifferentiated fever in feedlot calves in western Canada.

A study was conducted in western Canada to evaluate the efficacy of florfenicol for the treatment of undifferentiated fever (UF) in feedlot calves. One hundred and twenty-five recently weaned, auction market derived, crossbred, beef steer calves suffering from UF were allocated to 1 of 2 experimental groups as follows: florfenicol, which was intramuscular florfenicol administered at the rate of 20 mg/kg body weight at the time of allocation (day 0) and again 48 h later; or control, which was intramuscular saline administered at the same volume as florfenicol at the time of allocation and again 48 h later. Eighty-four calves were allocated to the florfenicol group and 41 calves were allocated to the control group. Outcome measures describing animal health, body weight, and rectal temperature parameters were used to determine the efficacy of florfenicol for the treatment of UF. The 1st relapse of UF, 2nd relapse of UF, overall mortality, bovine respiratory disease mortality, and haemophilosis mortality rates were significantly (P < 0.05) lower in the florfenicol group than in the control group. Animals in the florfenicol group were significantly (P < 0.05) heavier at day 15 and day 45 than animals in the control group. The rectal temperature on days 1, 2, 3, and 4 of animals in the florfenicol group was significantly (P < 0.05) lower than in the control group. In addition, the change in rectal temperature from day 0 to day 4 was significantly (P < 0.05) different between the experimental groups. The results of this study demonstrate that florfenicol is an efficacious antimicrobial for the treatment of UF.     

A field investigation of the economic impact of respiratory disease in feedlot calves

A trial involving 512 beef calves was conducted in a commercial research feedlot to determine the effect of bovine respiratory disease (BRD) on performance parameters and carcass characteristics. Two hundred and fifty-six calves that were deemed to be “sick” (S) from BRD were allocated to 16 pens and 256 calves that were considered to be “well” (W) were allocated to another 16 pens. The outcome variables that were measured included average daily gain (ADG), daily dry matter intake (DDMI), dry matter intake to gain ratio (DM:G), BRD treatment rate, death loss, carcass traits, and net profit per pen.

The data were partitioned into several time intervals including processing (P) to day −1, day 0 to day 27, day 28 to day 55, day 56 to day 83, day 84 to day 111, day 112 to day 139, day 140 to slaughter, day 0 to slaughter (0-Slaugh), and processing to slaughter (P-Slaugh). However, the most important interval was from processing to slaughter.

For the interval P-Slaugh, there were no significant (p≥0.05) differences between the S and W groups with respect to ADG and DM:G. Also, for the interval 0-Slaugh, the DDMI was similar for both groups. There were no significant (p≥0.05) differences between the S and W groups for carcass weight, average fat, grade fat, rib eye area, marbling score, cutability estimate, or carcass grade distribution.

The BRD treatment rates in the S and W groups were 6.6% and 4.7%, respectively. The mortality rates in the S and W groups were 0.78% and 0.39%, respectively. Also, there were no deaths attributable to BRD in either group.

In the economic model, there was no significant (p≥0.05) difference between the S and W groups with respect to net profit per pen.

We conclude that this trial did not validate the concept that BRD impacts performance parameters, because a sufficient disease challenge was not present. However, this study provides several observations that will enhance the experimental design of future studies that attempt to quantify the total economic impact of BRD.